MA31293B1 - Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire - Google Patents

Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire

Info

Publication number
MA31293B1
MA31293B1 MA32248A MA32248A MA31293B1 MA 31293 B1 MA31293 B1 MA 31293B1 MA 32248 A MA32248 A MA 32248A MA 32248 A MA32248 A MA 32248A MA 31293 B1 MA31293 B1 MA 31293B1
Authority
MA
Morocco
Prior art keywords
mask
treatment
copper salt
macular degeneration
coated copper
Prior art date
Application number
MA32248A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Georg Ludwig Kis
Jacques Vandermander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31293(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31293B1 publication Critical patent/MA31293B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA32248A 2007-03-23 2009-10-02 Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire MA31293B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (en) 2007-03-23 2008-03-19 Use of a masked or coated copper salt for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
MA31293B1 true MA31293B1 (fr) 2010-04-01

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32248A MA31293B1 (fr) 2007-03-23 2009-10-02 Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire

Country Status (26)

Country Link
US (1) US20080233182A1 (enExample)
EP (1) EP2124973B1 (enExample)
JP (1) JP2010521534A (enExample)
KR (1) KR101688656B1 (enExample)
AR (1) AR065791A1 (enExample)
AU (1) AU2008231847B2 (enExample)
BR (1) BRPI0809258B8 (enExample)
CA (1) CA2681514C (enExample)
CL (1) CL2008000804A1 (enExample)
CO (1) CO6230993A2 (enExample)
DK (1) DK2124973T3 (enExample)
EC (1) ECSP099700A (enExample)
ES (1) ES2542694T3 (enExample)
GT (1) GT200900251A (enExample)
IL (1) IL201109A (enExample)
MA (1) MA31293B1 (enExample)
MX (1) MX2009010244A (enExample)
MY (1) MY164520A (enExample)
NZ (1) NZ579852A (enExample)
PE (1) PE20090186A1 (enExample)
PL (1) PL2124973T3 (enExample)
PT (1) PT2124973E (enExample)
RU (1) RU2009139002A (enExample)
TN (1) TN2009000387A1 (enExample)
TW (1) TW200904456A (enExample)
WO (1) WO2008116806A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법
AR118962A1 (es) * 2019-05-22 2021-11-10 Bayer Consumer Care Ag Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (enExample) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ580938A (en) * 2004-07-09 2011-04-29 Robert Sabin Composition and methods of use for treatment of mammalian diseases
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법

Also Published As

Publication number Publication date
DK2124973T3 (da) 2015-06-22
AR065791A1 (es) 2009-07-01
KR20100015799A (ko) 2010-02-12
US20080233182A1 (en) 2008-09-25
EP2124973A1 (en) 2009-12-02
JP2010521534A (ja) 2010-06-24
WO2008116806A1 (en) 2008-10-02
RU2009139002A (ru) 2011-04-27
KR101688656B1 (ko) 2016-12-21
MY164520A (en) 2017-12-29
AU2008231847A1 (en) 2008-10-02
ECSP099700A (es) 2009-11-30
PE20090186A1 (es) 2009-03-20
CA2681514C (en) 2016-11-08
BRPI0809258B1 (pt) 2019-10-01
PT2124973E (pt) 2015-09-01
BRPI0809258A2 (pt) 2014-09-23
BRPI0809258B8 (pt) 2021-05-25
CL2008000804A1 (es) 2008-10-24
EP2124973B1 (en) 2015-05-27
ES2542694T3 (es) 2015-08-10
CO6230993A2 (es) 2010-12-20
TW200904456A (en) 2009-02-01
CA2681514A1 (en) 2008-10-02
MX2009010244A (es) 2009-10-26
TN2009000387A1 (en) 2010-12-31
IL201109A (en) 2016-10-31
AU2008231847B2 (en) 2012-12-06
NZ579852A (en) 2012-03-30
PL2124973T3 (pl) 2015-10-30
IL201109A0 (en) 2010-05-17
GT200900251A (es) 2018-10-08

Similar Documents

Publication Publication Date Title
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
RU2018104725A (ru) Феноксигалогенфениламидины и их применение в качестве фунгицидов
MA31419B1 (fr) Derives de pyridine
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques.
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
ATE533489T1 (de) Behandlung von multiplem myelom
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA54386B1 (fr) Modulateurs de trex1
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
ATE110364T1 (de) Substituierte chinoline.
MA31293B1 (fr) Utilisation d'un sel de cuivre masque ou enrobe pour le traitement d'une degenerescence maculaire
MA37719A1 (fr) Dérivés de pyrimidinone en tant qu'agents anti-malaria
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
MA27501A1 (fr) Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander